FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3677290014 | Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3677291013 | Carbidopa 25 mg and entacapone 200 mg and levodopa 100 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 2466313012 | Carbidopa 25mg/levodopa 100mg/entacapone 200mg tablet (product) | en | Fully specified name | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 2472513014 | Carbidopa 25mg/levodopa 100mg/entacapone 200mg tablet | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 2478141013 | Levodopa 100mg/carbidopa 25mg/entacapone 200mg tablet | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 3486786017 | Product containing carbidopa 25 mg and levodopa 100 mg and entacapone 200 mg/1 each oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3495136014 | Product containing carbidopa 25 mg and levodopa 100 mg and entacapone 200 mg/1 each oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3501955014 | Carbidopa 25 mg and levodopa 100 mg and entacapone 200 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3569998016 | Product containing only carbidopa 25 mg and levodopa 100 mg and entacapone 200 mg/1 each oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3569999012 | Product containing only carbidopa 25 mg and levodopa 100 mg and entacapone 200 mg/1 each oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3677290014 | Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3677291013 | Carbidopa 25 mg and entacapone 200 mg and levodopa 100 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3677292018 | Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Carbidopa+levodopa+entacapone | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Carbidopa | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Levodopa (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Entacapone (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Conventional release oral tablet (dose form) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product manufactured as oral dose form (product) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Carbidopa | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Carbidopa | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 25 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Levodopa (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Levodopa (substance) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 10^2 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Entacapone (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Entacapone (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 200 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Carbidopa | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 25 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Levodopa (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 10^2 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Levodopa (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Entacapone (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Carbidopa | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product containing carbidopa and entacapone and levodopa in oral dose form (medicinal product form) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Count of base of active ingredient | trois | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product containing only carbidopa and entacapone and levodopa in oral dose form (medicinal product form) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Plays role | Antiparkinson therapeutic role | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Levodopa (substance) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Carbidopa | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Entacapone (substance) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Carbidopa | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
| Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Entacapone (substance) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets